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The field of mechanical circulatory support is evolving rapidly and new data are 
published at a rate that can be overwhelming. In this review, we summarized 
some of the publications from 2014 that we think are particularly important. We 
have also included a few selected papers from the end of 2013 and the very 
beginning of 2015. Some of this overlap reflects the inevitable delay between 
online and paper publications. 
Readers who wish to supplement this review or argue with the author’s 
statements are encouraged to do so on our Facebook page at 
https://www.facebook.com/TheVADJournal. 
Outcomes 
The sixth annual report of the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) presented data for 10,000 patients on long 
term ventricular assist devices (VADs). Actuarial survival on continuous-flow 
pumps is 80% at 1 year and 70% at 2 years. A total of 141 centers are approved 
for destination therapy implants (1). 
McIlvennan et al. (2) reviewed the data systematically and summarized the data 
from clinical trials and registries that relate to outcomes on continuous flow 
LVADs (Figure 1). 
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Fig 1.  Estimated Actuarial Survival of continuous flow LVAD; reproduced 
from McIlvennan et al. (2), with permission 
 
Interestingly, mortality in LVAD patients is improving but morbidity remains 
approximately the same. Khazanie et al. (3) analyzed outcomes between 2006 
and 2011 for patients who received LVADs and who were Medicare 
beneficiaries. They concluded that short and long term mortality decreased while 
the admission rate remained stable at about 80%. Unlike mortality, admission 
rate did not depend on the number of implants performed by the center. We look 
forward to seeing the data from 2011 onwards as we predict that morbidity will 
drop as centers gain experience in post-LVAD care. 
Good outcomes with LVAD implantation in uninsured patients in the USA were 
reported by Rajagopalan et al.(4). This study analyzed patients from our 
institution. Almost all of them benefited from a device. 
 
Outcomes for specific devices were also reported in 2014. Data from the post-
market Registry to Evaluate the HeartWare Left Ventricular Assist System 
(ReVOLVE) confirmed excellent outcomes in 254 commercial implants with a 
mean duration of support of 363 ± 280 days (median 299.5 days). The survival 
was 87% at 6 months, 85% at 1 year, 79% at 2 years and 73% at 3 years (5).  
Bernhardt et al. (6) shared European experience with HeartWare (HeartWare 
Inc., Framingham, MA) for isolated right ventricular (RV) dysfunction with 
preserved left ventricular (LV) function. There were a total of 8 such patients in 
the EUROMACS registry, all with acute RV failure due to acute myocardial 
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infarction, failure to wean from cardiopulmonary bypass, or post-cardiotomy 
syndrome. Although only 3 patients survived to either heart transplant or 
recovery, most programs lack experience with these types of patients, so the 
data are very valuable. 
 
Short term hemodynamic support 
To our knowledge, Stretch et al. (7) presented the first data quantifying the 
impact on outcomes of short-term hemodynamic support. In adult patients, who 
received receiving short-term mechanical circulatory support (MCS) in the United 
States from 2004 to 2011, use of percutaneous devices (Tandem-Heart and 
Impella) for short-term MCS increased by 1,511% compared with a 101% 
increase in non-percutaneous devices (Centrimag and some older devices). 
Intra-aortic balloon pump and ECMO were excluded from the analyses. The most 
rapid growth started in 2008. Mortality rates in patients on short-term support 
declined from 41.1% in 2004 to 2007 to 33.4% in 2008 to 2011 (p for trend = 
0.027). Mortality in cardiogenic shock decreased from 51.6% to 43.1% (p for 
trend = 0.012). Hospital costs also declined (p for trend = 0.011). 
Candidate Selection 
Several papers in 2014 focused on candidate selection and presented valuable 
data relating to indications and contraindications/precautions. 
RV failure 
An analysis of INTERMACS data showed that more than 70% of patients with 
chemotherapy (anthracycline) induced cardiomyopathy are female. These 
individuals required more right ventricular assist device support than patients with 
non-ischemic and ischemic cardiomyopathy (19% vs.11% versus 6%, p=0.006) 
(8). 
Obesity 
An article by Chaudhry et al. (9) showed that LVADs can be implanted in very 
obese patients, who can subsequently undergo a weight reduction surgery. Six 
morbidly obese patients (body mass index 47.6 ± 3.0 kg m-2), half of them 
already on LVAD support, underwent laparoscopic sleeve gastrectomy. One of 
the three LVAD patients developed pump thrombosis and required pump 
exchange. Surgery in the other two patients was uneventful. At median follow-up 
of 22 months, mean body mass index decreased to 34.3 ± 2.4 kg m-2. All six 
patients became transplant candidates. 
Frailty 
Handgrip strength was reported as an easy to measure variable that predicts 
outcomes in patients with LVADs. When measured in 72 patients before and 
after LVAD implantation, grip strength increased by 18.2 ± 5.6% at 3 months and 
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by 45.5 ± 23.9% at 6 months.  Patients with a handgrip strength <25% of body 
weight had an increased risk of mortality and increased postoperative 
complications (10). Frailty before destination LVAD implantation was also 
associated with increased risk of death (11). 
Adult congenital disease 
One of the most challenging tasks in cardiology is caring for adults with single 
ventricle physiology. Failure of the systemic morphologic right ventricle is 
frequently encountered in congenitally corrected transposition of the great 
arteries or after atrial switch for transposition of the great arteries. Peng et al. 
(12) reported their experience with 7 such patients (mean age 36 years) who 
received HeartWare devices. 
There were no early deaths within 30 days. The rate of stroke was high at 43% 
(hemorrhagic and ischemic combined). Overall, 6 of the 7 patients (86%) 
returned home. More specifically, 3 patients (44%) received a cardiac transplant, 
2 patients (28%) died of non-cardiac causes, and the remaining 2 individuals 
(28%) continued on VAD support for a median length of 232 days. The three 
patients that received transplants showed an improvement in median 
transpulmonary gradient (18.5 mm Hg to 8.0 mm Hg) in repeat catheterizations. 
The authors conclude that LVAD is a reasonable strategy for such patients.  
New data from experiments with pigs may also help to advance the treatment of 
congenital heart defects. A porcine model of Fontan physiology was created by 
surgically placing catheters from the inferior and superior cava veins to the 
pulmonary artery. A VAD was then implanted into the common graft to facilitate 
pulmonary circulation. Arterial pressure and aortic flow, which both decreased 
dramatically with Fontan physiology, returned to baseline after the VAD implant. 
Similarly favorable changes occurred within the systemic venous circulation (13). 
This raises the hope of using VADs as a bridge to transplant in failing Fontans. 
LVADs and Co-Morbid Conditions 
Arrhythmias 
There are still no clear results showing how to manage arrhythmia in patients 
with LVADs.  
Atrial arrhythmia 
A particularly interesting study was published by Sean Pinney’s group from 
Mount Sinai, New York. In retrospective review, paroxysmal or persistent atrial 
fibrillation was present in 51.9% of patients. While paroxysmal atrial fibrillation did 
not adversely affect outcomes, the persistent form of fibrillation was associated 
with an increased composite endpoint of death or HF hospitalization (HR: 3.54; 
95% CI 1.52 to 8.25; p < 0.01). The difference was mainly driven by HF 
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hospitalizations. These patients also had thromboembolic events at higher 
international normalized ratios (INRs) (14).  . 
Brisco et al.(15) also showed that atrial arrhythmias in HeartMateII trials were 
associated with lower quality of life and slower functional recovery but did not 
influence mortality. Unfortunately, the authors did not define atrial arrhythmias in 
their report and, moreover, analyzed supraventricular arrhythmias separately. We 
presume that the majority of the patients had atrial fibrillation but there may be 
alternative explanations. 
Ventricular arrhythmia 
It is well known that ventricular tachycardia/fibrillation is generally well tolerated 
in patients with LVADs. To underscore this, a case report published by Naito et 
al.(16), describes a patient who was supported by an LVAD through incessant 
ventricular fibrillation, resistant to all anti-arrhythmics, for 18 months. 
On the other hand, a study from the Cleveland Clinic demonstrated that cardiac 
output in patients on LVAD support drops by about 30% during ventricular 
fibrillation. These tests were performed in the electrophysiology laboratory during 
defibrillation threshold testing. Cardiac output returns to baseline seconds after 
successful defibrillation (17). This finding explains why many LVAD patients are 
symptomatic during ventricular arrhythmias even though they don’t die. 
Ablation for ventricular tachycardia remains a topic of interest. Garan et al. (18) 
reported successful ablation of ventricular tachycardia in 6 out of 7 patients with 
LVADs.  In almost half of the patients, the source of tachycardia was located in 
the apex. 
Cardiac resynchronization devices, when compared to implantable defibrillators, 
did not significantly improve mortality, all-cause hospitalization, LV dimensions, 
or incidence of arrhythmias in LVAD recipients (19). 
LVAD and diabetes 
Several reports in 2014 confirmed Uriel et al.’s 2011 discovery (20) that diabetes 
improves after LVAD. Our own group reported that HbA1C, which was 7.6 ± 1.6 
% before LVAD, decreased to 5.7 ± 0.9 % within 3 months of the implant and 
remained below the pre-LVAD level for at least 12 months. (21). Choudhary et 
al.(22) also found that fasting blood glucose improved from 136 ± 35 to 108 ± 29 
mg dl-1 post-LVAD (p < 0.001), and daily insulin dose decreased from 43 ± 37 to 
29 ± 24 units (p = 0.02). Mohamedali et al.(23) presented similar findings and 
added that some patients were able to completely discontinue oral 
hypoglycemics. Subauste et al. also published related data (24). 
The mechanisms underlying this phenomenon remain unclear. Koerner et al. 
measured cortisol and plasma catecholamine levels and found that both 
decreased after the LVAD implant. (25). This may implicate systemic 
inflammatory and stress responses. Another possibility is that improved 
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hemodynamics in the pancreas and/or peripheral tissues increase glucose 
metabolism. Irrespective of the mechanism, diabetes should not be considered a 
contraindication to LVAD. 
LVAD and valves 
An excellent review of valvular problems in LVAD patients was published by the 
group from Duke (26). The summary table is reproduced below (Figure 2). 
 
Fig 2.  Approach to valvular problems in LVADs; reproduced from Wang et 
al. (26), with permission 
Detailed analysis of the clinical data for 382 patients supported by HeartWare 
devices in the ADVANCE trial demonstrated that concurrent valve surgery during 
the device implantation resulted in higher postoperative early RV failure but 
similar one year survival compared with implantation only (27). Valve surgeries 
were performed in ~20% of patients (56 tricuspid, 13 aortic, and 6 mitral valve 
procedures). Unoperated severe tricuspid regurgitation was associated with 
higher odds of late postoperative RV failure. 
 
	  
	  
	  
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.06  Page 7 of 23 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Analysis of the much larger cohort of 1106 patients who received HeartMate II 
devices in clinical trials showed similar results. About 20% of patients had 
concomitant valve procedures and their survival was impacted. 
Patients undergoing both LVAD implantation and valvular surgery were older, 
had higher blood urea nitrogen levels, higher central venous pressure, and 
decreased right ventricular stroke work index. Their 30-day mortality was higher 
(10.3% versus 4.8% for LVAD alone, P = 0.005). These patients also had higher 
rates of right heart failure and received more right ventricular assist devices (28). 
Tricuspid valve 
Extra caution may be appropriate when considering concomitant tricuspid valve 
repair in tricuspid regurgitation. Robertson et al. (29) analyzed the outcomes for 
588 patients from 115 institutions who had moderate to severe tricuspid 
regurgitation and who underwent tricuspid valve repair when they received their 
LVAD. The most common procedure was annuloplasty. The authors concluded 
that tricuspid valve repair was associated with an increased risk of post-operative 
renal failure, dialysis, reoperation, greater transfusion requirement, longer times 
on a ventilator and in the intensive care unit, and longer hospital stay. There was 
no effect on operative mortality or post-operative RVAD requirement. Long term 
outcomes were not reported in this paper. 
On the other hand, some single center studies, such as the one from Henry Ford 
Hospital, Detroit, MI, saw survival benefit in concomitant tricuspid valve repair 
(30). 
Aortic valve 
The Columbia university program summarized their experience with aortic 
regurgitation in 232 LVAD patients. They repaired the aortic valve in 43 of these 
individuals at the time of implant. After three years on support, about 40% of 
patients developed at least moderate aortic regurgitation. This was particularly 
common if the aortic valve remained closed during LVAD support. Seven of the 
patients with moderate or severe aortic insufficiency developed symptoms of 
heart failure, requiring surgical intervention (31). 
Interestingly, British investigators found that the incidence of aortic regurgitation 
was lower in HeartMate II than in HeartWare recipients (43.1% versus 65.7%, p 
=0.035) (32). Overall, de novo aortic regurgitation after LVAD implant did not 
affect survival (33). 
For the first time, based on the INTERMACS data, it was shown that closure of 
aortic valve during LVAD implant compromises survival (34). 
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Innovative approaches to valvular problems, published in 2014, include 
transcutaneous aortic valve replacement for severe aortic regurgitation (35), and 
transcutaneous aortic valve replacement via left ventricular assist device inflow 
cannula (36). 
Resuscitation in LVADs 
In a small case series, chest compressions during cardiac arrest in 8 LVAD 
patients did not result in dislodgement of the cannulae or other device 
complications (37).  
Another group of authors searched existing literature and fond 10 other cases of 
chest compression (longest duration of chest compression was 150 minutes), 
also without complications. In some cases, neurological function was regained. 
However, assessment of the efficacy of the compressions was not the objective 
of either study (38). 
Complications of the VADs 
Pump thrombosis 
Pump thrombosis was, perhaps, the leading topic of the year, with many 
excellent papers. The discussion was launched in late 2013 when the New 
England Journal of Medicine published the paper by Starling et al. (39) reporting 
abrupt growth in pump thrombosis (2.2% to 8.4%) between 2011 and 2013. This 
was observed at the Cleveland Clinic, Duke, and Barnes-Jewish. At the same 
time, the time from implant to pump thrombosis shortened from 18.6 to 2.7 
months. This increase was also apparent in an analysis of data from 
INTERMACS (40). 
Data suggest that increased lactate dehydrogenase (>600 U/mL for HeartMate II 
and >400 U/mL for Heartware) is the most reliable predictor of pump thrombosis 
(41), and some centers have adopted the policy of immediate hospitalization 
based on elevated LDH alone. The best way to treat patients who have elevated 
LDH but no clinical signs of pump thrombosis is still unclear. 
An echocardiographic method of the diagnosis of pump thrombosis was 
proposed by Estep et al. (42). These authors leveraged the principle that in a 
normally functioning LVAD, higher pump speed results in reduced LV 
dimensions, less opening of the aortic valve, and longer filling times (longer mitral 
E wave deceleration time). Specifically, the authors measured LV end diastolic 
dimension, aortic valve opening duration, and E wave deceleration time as they 
increased the revolutions per minute (rpm) from 8000 to 12000 in HeartMate II 
devices (2 minutes per stage, 1000 rpm increments). Thrombosis was indicated if 
patients had a less than a 0.6 cm reduction in LV end-diastolic dimension, less 
than an 86 ms shortening of aortic valve opening, and less than a 73 ms increase 
mitral E wave deceleration time. Matching one of these criteria predicted pump 
malfunction (normally due to thrombosis) with 100% sensitivity and 89% 
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specificity. Matching two parameters increased these values to 100% sensitivity 
and 95% specificity. 
A very innovative method of detecting pump thrombosis was proposed by the 
Berlin group. They recorded the sound produced by HeartWare devices and 
noticed that the acoustic spectrum was different if the pump contained a 
thrombus. Eight pumps were exchanged because of their acoustic signature and 
thrombi were confirmed in each case (43). 
In terms of treatment of pump thrombosis, eptifibatide, once again, appeared to 
cause more harm than good, with many bleeding events and very modest 
therapeutic benefits reported (44). A case series with bivalirudin also reported 
high recurrency rate, with most patients eventually receiving a transplant or pump 
exchange (45). There was an anecdotal report of good experience with 
argatroban (46). 
Complications were reported when investigators tried to facilitate intermittent 
opening of the aortic valve by decreasing the LVAD speed. Such practice 
increased the rate of thromboembolic events (47). This may be because high 
flow rates dissipate heat from the LVAD more effectively than low flow conditions. 
Karimi et al.(48) tested using thrombelastography to adjust antiplatelet therapy in 
57 HeartMate II recipients. These patients were followed for about a year. 
Specifically, the authors adjusted aspirin and dipyridamole to maintain maximum 
amplitude (a measure of clot strength) between 60 and 70 mm. This allowed 
aspirin and dipyridamole to be used in lower doses in some patients. The rate of 
bleeding events was 0.21 per patient-year, which was lower than historic controls 
collected from the literature. Specifically, in 7 other studies where no tests were 
used to adjustment of antiplatelet therapy, the rate of bleeding events was 0.49 
events per patient-year. 
Gastrointestinal bleeding 
Much attention was paid in 2014 to the nature of acquired von Willebrand 
syndrome. It is now widely accepted that the sheer stress produced by a 
continuous flow pump destroys multimers of von Willebrand factor. The larger 
multimers capture more platelets and facilitate their adhesion and aggregation. 
The destruction of the multimers impairs hemostasis and causes bleeding. This 
year, several papers elucidated on the role of metalloprotease ADAMTS-13, 
which apparently plays an important role in destruction of this coagulation factor. 
In particular, Bartoli et al. (49) used a laboratory vortexer to mimic the effects of 
an LVAD on von Willebrand factor. Their control experiments showed that the 
vortexer modestly reduced the concentration of large von Willebrand factor 
multimers. Adding ADAMTS-13, the von Willebrand factor protease, substantially 
enhanced the degradation of the large multimers and also increased the 
concentration of degradation fragments. These effects are similar to those 
induced by LVADs. Bartoli et al. concluded that sheer stress alone is not enough 
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to destroy the von Willebrand factor. They also suggested that targeting 
ADAMTS-13 may preserve the multimers, prevent their cleavage into fragments, 
and reduce gastrointestinal (GI) bleeding in patients with LVADs. 
One potential strategy described by Bartoli et al. is to use tetracycline antibiotics. 
These drugs inhibit matrix metalloproteinases (such as the ADAMTS protease) 
and might therefore impact von Willebrand factor degradation. Doxycycline is an 
example of a tetracycline antibiotic that has been used safely for years (for 
example, for acne) and that could be tested relatively easily in patients who have 
LVADs. As an additional benefit, tetracyclin might help to prevent driveline 
infections caused by methicillin-resistant Staphylococcus aureus. 
Additional manuscripts presented anecdotal evidence that GI bleeding could be 
controlled with the following medications: 
• Danazol (200 mg BID) (50) 
• Octreotide (100 mcg SC BID in the hospital and then 20 mg depot 
IM monthly) (51). Other authors report 50 mcg SQ BID (52). 
• Thalidamide (50 mg BID with potential increase to maximum daily 
dose of 200 mg, reduce to 50 mg QOD if toxicity develops), 
monitor blood count while up-titrating, try decreasing the dose 
when therapeutic effect achieved (53,54). 
Additional strategies described in 2014 include double balloon enteroscopy. This 
was reported to provide a high diagnostic yield of 69%, and an even more 
impressive therapeutic effect of 89 %. These results were achieved using argon 
plasma coagulation, epinephrine injection, and/or hemoclip placement (55). 
Hirose et al. (56) suggested initiating work-up for GI bleeding with deep bowel 
enteroscopy and omitting the usual upper and lower endoscopy and capsule 
endoscopy because they are low-yield procedures. This approach appeared to 
reduce the number of procedures and transfusions and also to reduce costs. 
Unfortunately, not every hospital has the equipment for deep bowel enteroscopy. 
Several papers reported that anticoagulation in LVAD patients can be safely 
reversed. Data from the Henry Ford Hospital program described 38 reversals of 
anticoagulation in 25 patients using vitamin K at a mean dose of 10 ± 8 mg or 
fresh frozen plasma. Only one patient had a thromboembolic event within 30 
days of reversal (57).  
 
14 of 213 (6.5%) patients at the University of Minnesota had discontinuation of 
anticoagulation: 10 patients had warfarin discontinued and 4 had both aspirin and 
warfarin discontinued. Most of these interventions were for GI bleeding. The 
mean duration off warfarin was 392 days. There was only one pump thrombosis 
episode, and this occurred in the patient with surgical malpositioning of the LVAD 
cannula (58).   
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Infections in LVADs 
Several excellent papers were published in 2014 relating to infections. The 
importance of burying the velour portion of the HeartMate II driveline well under 
the skin was underscored by Singh et al (59). This technique improved driveline 
infection-free survival. 44.4% of patients had driveline infections when velour was 
exposed but the infection rate was only 8.8% when the exposed region was 
silicone.  
Yarboro et al. (60) shared experience from the University of Virginia where the 
driveline infection rate dropped from 20% to zero. They described, step by step, 
their approach to driveline care at every stage of LVAD implantation and follow-
up. 
Kretlow et al.(61) reported the use of antibiotic beads for salvage of LVADs with 
deep infection in the pocket. 17 of 26 patients with LVAD-related infections were 
cleared of their infection and many survived. Plastic surgery was often required 
to cover the device with a flap. 
A strong association between LVADs and blood stream infection was described 
by Trachtenberg et al.(62). Out of 149 patients who received an HMII device, 19 
patients (13%) had strokes (7 hemorrhagic and 12 ischemic). During the same 
period, there were 28 patients (19%) with persistently positive blood cultures and 
17 patients (11%) with intermittently positive blood cultures. Only persistently 
positive blood cultures were associated with an increased risk of mortality and 
with all cause cerebrovascular accident on multivariate analysis (OR 5.97, 
P=0.003). 
Recovery 
Diakos et al. (63) discovered, that, unlike animal models, human hearts do not 
develop cardiomyocyte atrophy as a result of prolonged mechanical circulatory 
support. Cardiomyocyte size (cross-sectional area) decreased after LVAD 
unloading but not beyond that of normal donor hearts. Other approaches that did 
not show evidence of myocardial atrophy included evaluation of ultrastructure 
using electron microscopy, analysis of cardiomyocyte glycogen content, and 
echocardiographic assessment of myocardial mass and left ventricular function. 
We note that patients were only followed for 6 months in this study and, in our 
opinion, atrophy could still occur after longer period of support. 
Some genetic predisposition to myocardial recovery while on LVAD support was 
demonstrated by Posch et al.(64). They studied a connective tissue growth 
factor that is associated with adaptive cardiomyocyte hypertrophy. 
Homozygosity of the promoter-activating G allele was overrepresented in 
patients with cardiac recovery (50%) relative to patients who did not recover 
(17%).  
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Non-Cardiac Surgery 
An interesting survey of current practices was published by Sheu et al. (65). 72% 
of inpatient endoscopic procedures were performed in the endoscopy suite. Most 
(59%) procedures were also completed by a solo practitioner with a 1:1 staffing 
ratio. LVAD coordinators were present for more than 80% of all procedures. Both 
endoscopy and surgical patients used recovery units and intensive care units for 
recovery. Patients who had non-cardiac surgery recovered in the intensive care 
beds more often than those who had endoscopy (45.5% versus 29.1%, p < 
0.001). 18% of endoscopy patients recovered on site. An arterial line for blood 
pressure monitoring was inserted in ~50% of the endoscopy patients and in 71% 
of surgical patients. Institutions with high LVAD volumes used less invasive 
monitoring. 
Imaging in LVADs 
Two papers that focus on echocardiographic evaluation of LVAD patients and 
which we judge to be particularly important were published by Jerry Estep and 
co-authors. One of the manuscripts discussed using echocardiography to 
diagnose pump thrombosis (42) and was discussed earlier in this article. 
The second article compared invasive and echocardiographic hemodynamic data 
and found that hemodynamic echo measurements are valid in patients supported 
by continuous flow LVADs. Good correlations were obtained between invasively 
measured and non-invasively estimated values for mean right atrial pressure (r = 
0.863; p < 0.0001), systolic pulmonary artery pressure (r = 0.880; p < 0.0001), 
right ventricular outflow tract stroke volume (r = 0.660; p < 0.0001), and 
pulmonary vascular resistance (r = 0.643; p = 0.001). Furthermore, the authors 
proposed an algorithm that was able to distinguish between patients with normal 
and elevated left ventricular end diastolic pressure with 90% accuracy (Figure 3) 
(66). 
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Fig 3.  Echocardiography algorithm for estimation of left ventricular filling 
pressure in LVAD patients; reproduced from Estep et al. (66), with 
permission 
A comprehensive review of echocardiographic assessment of patients who are 
being considered for LVAD treatment as well as patients who are already on 
LVAD support was published by Todaro et al (67). We found the following 
algorithm of assessment of the right ventricle prior to implant very helpful (Figure 
4). 
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Fig 4.  Echocardiographic assessment of the right ventricle before LVAD 
implantation; reproduced from Todaro et al. (67), with permission 
Finally, a nice series of images showing how PET/CT can be used to find the 
exact location and the extent of LVAD-related infections was published by Kim et 
al (68). 
New Pumps 
Several interesting new pumps were introduced or developed further in 2014.  
A HeartWare MVAD 
A HeartWare MVAD (HeartWare, Miami Lakes, FL) pump (length 50mm, 
diameter 21 mm; maximum flow 7–8 liters/min) was combined with a novel inflow 
cannula and tested in sheep with good results (69) (Figure 5). 
Impella for RV support 
In January of 2015, the FDA approved a percutaneous right-sided Impella PR 
(right peripheral; Abiomed, Danvers, MA) for 14 days of support for right 
ventricular failure under a humanitarian device exemption (Figure 6). The 
approval was based on the results of the RECOVER-RIGHT study which is still, 
to the best of our knowledge, unpublished. According to clinicaltrials.gov, the 
goal of this study is to show that using the Impella RP is safe and feasible and 
that the device provides a hemodynamic benefit in patients with right ventricular 
failure (https://clinicaltrials.gov/ct2/show/record/NCT01777607). 
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Fig 5.  Miniaturized HeartWare LVAD; reproduced from Schima et al. (69), 
with permission 
Data from the trial were presented by William O'Neill at the TCT meeting in 2014. 
A total of 30 patients were supported with a right-sided Impella, with a 30 day 
survival of 73%. Patients who developed right ventricular failure after receiving 
an LVAD had a mean survival of 83.3% while patients with right ventricular failure 
due to acute myocardial infarction or postcardiotomy syndrome had a mean 
survival of 58.3% (Abiomed press release at 
http://investors.abiomed.com/releasedetail.cfm?ReleaseID=871213). 
 
Additional positive data were published by Cheung et al.(70) from Vancouver, 
British Columbia, Canada. They presented a retrospective analysis of 18 
patients. All of these individuals were on intravenous inotropes, 39% on inhaled 
nitric oxide, 39% on intra-aortic balloon counterpulsation, and 11% survived 
cardiac arrest. Device implantation increased the mean cardiac index from 2.1 to 
2.6 L min-1 m-2 (p=0.04) and reduced central venous pressure from 22 to 15 mm 
Hg (p  < 0.01). 14 of the 18 patients had their Impella device explanted due to 
recovery. The other 4 patients died on support. Survival to 30 days was 72% and 
to 1 year was 50%.  
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Neither of the above studies compared outcomes with Impella support to 
outcomes without an Impella. 
 
Fig 6.  Impella RP (right peripheral); reproduced from Cheung et al. (70), 
with permission 
The Synergy CircuLite for partial support 
The Synergy Micro-pump (HeartWare Inc, Framingham, MA) is the smallest 
implantable LVAD that is currently available and can produce flows of up to 4.25 
L min-1. This device was tested in 7 INTERMACS class 1–2 patients and 6 
INTERMACS class 3–4 patients. The mean support times for the two groups 
were 108 ± 114 days and 238 ± 198 days respectively. The overall survival was 
comparable for the two groups, with one late death in each group, log-rank p = 
0.608). Two patients from the high-risk group were upgraded to a full-support 
LVAD after 65 ± 85 days of support with the Synergy Micro-pump. The authors 
concluded that the pump is a feasible approach even in very high risk patients 
(71).   
Mohite et al. (72) described an algorithm to check for pump thrombosis. 
Apparently, the Synergy speed fluctuates periodically at 10-second intervals to 
reduce the probability of thrombosis. If the pulse oximeter waveform was 
recorded from the index fingers of the left and right hand, patients with normal 
device function had a more pronounced variation (giant wave) in the trace from 
the right hand than from the left. These giant waves coincided with the variation 
in sound detected by auscultation using a stethoscope positioned over the right 
infra-clavicular pocket. 
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